During a screening program for microbial metabolite that promote the proliferation of bone marrowcells we isolated three lipopeptides, TAN-1511 A (1), B (2 and G (3) , from the culture broth of Streptsporangiun amethystogenes subsp. fukuiense AL-234561).
Werevealed the structure of these components, excep for the configuration of the 2-amino-6,7-dihydroxy-4 thiaheptanoic acid (ADTA)moiety1}. They were obtain ed from the culture broth in very low yields and an mixtures of molecules containing fatty acids of differen lengths; mainly (9,0'-diacylated with palmitic acid anc 7V-acylated with isomyristic acid or myristic acid1} Therefore, it was necessary to synthesize them as a singli molecule in large amounts for further investigations o their biological activities. In this paper, we describe th< synthesis, structure-activity relationships and in v/v< effects of TAN-151 1 analogues. Chemistry Synthesis of ADTAMoiety We first targeted the synthesis of TAN-1511 A an alogues having palmitoyl and myristoyl residues as th< ester and amide fatty acids, respectively.
The synthesi of ADTAderivatives in high diastereomeric purity ha been reported by Metzger et al.2) and Achiwa et al.3~5] Amongthem, we adopted Metzger's method using ai optically active glycidol and the A^-9-fluorenylmethoxy carbonyl-L-cysteine ter/-butyl ester, Fmoc-L-Cys-OfBu2: because this procedure was convenient and the reactioi yields were high. After the reduction of 7V,7V'-bis-Fmoc L-cystine bis-tert-buty\ ester, (Fmoc-L-Cys-OtBu)2, into
Fmoc-L-Cys-O'Bu with zinc, the addition of (R)-(+)-glycidol to the mixture should yield (2i?,6i?)-2-(9-fluorenylmethoxycarbonyl)amino-6,7-dihydroxy-4-thiaheptanoic acid tert-buty\ ester (4a) according to the reaction mechanism.
Four diastereomers of ADTAderivatives (4a~4d) were prepared from (R)-(+) or (S)-(-)-glycidol and l or D-cystine as described2) and shown in Fig. 1 . The hydroxyl groups were acylated with excess palmitic acid in the presence of 7V,7V'-diisopropylcarbodiimide (DIC) and a catalytic amount of 4-dimethylaminopyridine (DMAP).Subsequent treatment with trifluoroacetic acid (TFA) to remove the tert-buty\ ester afforded the desired 2-(9-fluorenylmethoxycarbonyl)amino-6,7-bis(palmitoyloxy)-4-thiaheptanoic acids (5a~5d).
Synthesis of the Peptide Moiety
The peptide moiety of 1 was synthesized starting from This article is a special contribution in honour of Professor Satoshi Omura's 60th birthday. nene-2,3-dicarboximide (HONB) method to afford the protected peptide (6) as shown in Fig. 2 . The Z-group in each step was removed by catalytic hydrogenation.
Synthesis of TAN-1511 A Analogues
The peptide (6) was coupled with each diastereomer of 5a~5d by the DIC-HONBmethod and subsequent removal of the Fmoc-group with piperidine afforded amino analogues (7a~7d) (Fig. 3) . After 7V-acylation with myristic acid in the presence of l-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (water soluble carbodiimide, WSC) and 1-hydroxybenzotriazole (HOBT), the tert-butyl groups were finally removed with TFA to obtain the desired analogues (8a~8d). TV-Free analogues (9a~9d) were also prepared by deprotecting 7a~7d.
Stereochemistry of TAN-151 1 Although ADTAwas scarcely detected in the 6m hydrochloric acid hydrolysates of1, 2 and 3, it was readily HpfprtpH aft fr VivHrnivQiQ with A\n mptli^rip cnifrmir' Qr»ir1 (110°C, 12hours). ADTA derived from TAN-1511 complex was observed on HPLCat retention time of 20.3 minutes after treatment with o-phthalaldehyde and 7V-acetyl-L-cysteine. Whenfour diastereomers of ADTA obtained from 4a~4d were analyzed under the same conditions, the (2R96R), (2R,6S), (2S,6R) and (2S96S) isomers gave peaks at 20. 3, 20.2, 21 .0 and 21.0minutes, respectively, indicating that the C-2 position of the ADTAresidue has the R cofiguration. Whereas the XHNMRspectrum of 1 closely resembled those of the IRfiR and 2S£S diastereomers (8a and 8d) except for the fatty acid residue in which the natural sample includes a variety of fatty acids, there were some Table   1 , these protons of 1, 8a and 8d were observed at 5 2.69ppm. However, those of 8b and 8c were observed at S 2.74ppm. Since the 2R configuration of the ADTA residue of 1 was already determined, this finding revealed that the configuration of the C-6 position is also R. Therefore, the structures of 1, 2 and 3 were deduced as shown in Fig. 4 .
Modification of the Peptide Moiety At the beginning of the investigation concerning structure-activity relationships, we first synthesized derivatives with various peptide sequences. Like 6, the ter/-butyl group was adopted in protection of hydroxyl and carboxyl groups of peptide moieties. Compounds lla~llg were obtained by coupling 5a, having were prepared by deprotecting lla~llg with TFA.
Modification of the O-acyl Groups
To modify the (9-acyl groups, compound 4a was used as the starting material (Fig. 6) 
Biological Activity and Discussion
The effect of the synthesized compounds on the proliferation of bone marrowcells (BMC)was examined (Tables 2 and 3 ). Among the compounds (8a~8d) which have different configurations of the ADTAmoiety, only the 2^,6^-analogue (8a) showed activity of the same potency as natural TAN-1511A (1). The configuration of 1 is supported by this result. The corresponding TV-free derivative (9a) also had high activity. When the peptide sequence was shortened (12a and 12b), the activity was rather weaker than that of 8a. The activity, however, was increased by replacing the glycine moieties of 12b with glutamic acids (12c~12e). The TV-free derivatives (13a~13c and 13e) were more potent than the corresponding./V-myristoyl derivatives and the introduction of glutamic acids was also effective. Introducing the D-isomer of glutamic acid to 12f and 13f did not change the activity compared with that of 12g and 13g.
The compoundswere further evaluated in mice with leukocytopenia (WBC). The effects of the TV-myristoyi derivatives were similar ( Table 3) . As shown in BMC assay, however, replacing TV-myristoyl with TV-free was also effective in vivo (Table 3 ). In addition, the activities of these compounds with glutamic acid at the firsi position of the peptide sequence and at the carboxy terminal (13d and 13e) were 16 to 64 fold more potem than that of9a. On the other hand, the MECvalues oj the listed compounds did not differ from 9a by more than 4-fold in vitro. Although the mechanism responsible for the discrepancy in the in vivo and the in vitro activities remained to be further studied, an important role oi Table 4 shows that the O,0 '-distearoyl and -myristoyl derivatives (17 and 18) had the same degree of activity as the 6),0'-dipalmitoyl derivative (13d). When one of the 0-acyl groups was changed to a hexanoyl group, the activity was greatly diminished. These results revealed that both of the long chain acyl groups (C14 to C18) are necessary for the activity. Besides, as shownin Table 5 , among the TV-modified compounds, only the./V-myristoyl derivative (12d) had high activity similar to that of the TV-free derivative (13d).
Consequently, the following conditions are required ADTAmoiety must be (IRfiR), both the hydroxyl groups of ADTAmoiety should be esterified with the long chain acyl groups (C14 to C18), the amino group of the ADTA moiety must be free or acylated with the long chain fatty acid (ca. C14) and the peptide moiety must have glutamic acid as the component.
Though some compounds satisfied the above conditions, the solubilities of these compounds were too low to accurately determine their biological activities. To improve the low solubility, sodium salts of the four derivatives (13c, 13d, 13e and 13g) were prepared and their properties were examined. Solutions of the derivatives in 5% acetonitrile-0.5% aqueous sodium hydrogen carbonate was desalted by column chromatography using Diaion HP-20 to afford the sodium salt (32) (33) (34) (35) . While the disodium salts (32 and 35) were soluble in 5%aqueous glucose in concentrations up to lOmg/ml, the trisodium salts (33 and 34) were readily soluble in 5%aqueous glucose even at a concentration of lOO mg/ml. Moreover, though the particle diameter of the disodium salts (32 and 35) was 24.6 and 15.7nm in distilled water at a concentration of 1 mg/ml, respectively, that of the trisodium salts (33 and 34) was below the limit of measurement. Thus the trisodium salts were highly soluble in water. The acute toxiqities (LD50) of these sodium salts are summarizedin Table 6 . Though 13e (sodium free compound of 34) was the most potent compoundin the BMCand WBCassay, the toxicity of 34 was high in comparison with that of other compounds (32, 33 and 35) . Accordingly, taking into account the high solubility and the low toxicity, 33 was further evaluated using the mouse leukocytopenia model. Weexamined the effect of 33 upon the peripheral leukocyte counts after inducing experimental leukopenia in vivo using cyclophosphamide (CY). The leukocyte glucose were administered to the CYcontrol group in the same manner.
Blood samples were collected from the orbital angular vein. Means and standard deviations are presented. counts in CY-treated mice decreased to 25~30%of control level on day 4, and recovered to the control level on day 9. However, compound 33 administered at a dose of0.031 mg/kg once a day from days 1 to 5 restored the leukocyte counts to the control level on day 6; three days before the counts spontaneously recovered in CY-treated mice (Fig. 7) . The relationship between the dose of compound33 and leukocyte counts was a bell curve as shown in Fig. 8 . The minimum effective dose was 0.015 mg/kg/day, and the activity was maximal at a dose of 0.062mg/kg/day. The maximal leukocyte counts increased to double the control level, whereas those in mice treated with the maximum dose (1.0mg/kg/day) decreased to the control level. This was not derived from the different time courses of recovery of the leukocyte counts after various treatments of compound33, because the time courses in the lower (0.0078 -0.062 mg/kg/day) and higher dose groups (0.12-1.0mg/kg/day) were similar (data not shown). Therefore, an unknown mechanismwhich counteracts the overshoot of leukocyte counts might occur spontaneously in vivo, especially in mice treated with compound 33 at higher doses. Weexamined the effect of compound33 on colonystimulating factor (CSF) activity in serum and granulocytopoiesis in vivo ( Fig. 9 ). High levels of CSF activity were detected 2 -5 hours after a single administration of compound 33 in CY-treated mice. Various CSFs might be produced because there were three peaks of CSF activity during 2-15 hours. This remains to be clarified. Compound33 exhibited a selective restorative effect on the neutrophil count on day 6, at a dose of 0.0078mg/ kg/day. This was half of the minimum effective dose for the restoration of leukocyte counts. On the other hand, compound 33 did not restore lymphocyte counts ( Dose (mg/kg) CY and compound 33 were administered to mice as described in the legend to Fig. 7 . Differential leukocyte counts were obtained on day 6. Absolute neutrophil and lymphocyte counts were calculated from the differential and total leukocyte counts. ration of leukocyte counts in CY-induced leukopenia. Wefound that compound33 was also effective in other types of chemotherapy-induced experimental leukopenia using etoposide or a combination of CY, doxorubicin and vincristine, and in CY-induced leukopenia in colon carcinoma 26-bearing mice. The effective dose in these models was similar to that in CY-induced leukopenia described here (data not shown).
Experimental General IR spectra were measured with a Horiba FT-200 IR spectrophotometer using KBr pellets. Optical rotations were obtained with a JASCODIP-181 digital polarimeter. The XHNMR spectra were recorded on a Bruker AC-300 (300MHz) or AM-500 (500MHz) instrument. Chemical shifts (d) are reported in ppm down field from tetramethylsilane (TMS).
2-(9-Fluorenylmethoxycarbonyl)amino-6,7-bis(palmitoyloxy)-4-thiaheptanoic acid tert-butyl stirring for 30minutes at 0°C, (R)-(+)-glycidol (52.9 ml, 800 mmol) was added to the reaction mixture and stirred for 3 hours at 40°C. The mixture was concentrated to a small volume (350 ml) and precipitates were removed by filtration.
Saturated NaCl (1.0liter) was added to the filtrate and extracted with CH2C12(2 x 1.0liter). The organic layers were combined, dried over anhydrous Na2SO4 and concentrated.
The AcONa; flow rate, 1.0 ml/minute; detection, fluorescence; excitation at 360nm, emission at 440nm). Piperidine (0.1ml) was added to a solution of 4a~4d (10mg, 0.02mmol). The reaction mixture was stirred for 1 hour at room temperature, and concentrated. The residue was dissolved in TFA (0.5ml) and left for 30minutes at room temperature. The reaction mixture was concentrated and suspended in EtOAc (3.0 ml). The suspension was extracted with water and the aqueous layer was concentrated. The residue was analyzed after derivatization as described above. 27.5mmol) and DCC (5.67g, 27.5mmol) were added to the ice-cooled solution and the mixture was stirred for 2hours at 0°C, then the precipitates were removed by filtration.
A solution of Z-Thr(fBu)-OfBu (ll.Og, 30mmol) in MeOH(300ml) was hydrogenated over 10% Pd-C as a catalyst for 2hours at room temperature to give H-Thr('Bu)-O'Bu as a colorless oil. The filtrate described above and diisopropylethylamine (5.48ml, 31.5mmol) were added to an ice-cooled solution ofH-Thr(fBu)-OfBu in CH3CN(200 ml) and the mixture was stirred overnight at roomtemperature. The mixture was concentrated, suspended in EtOAc, then successively washed with 10% citric acid, saturated NaHCO3and water. The organic layer was dried over anhydrous Na2SO4 and concentrated. The residue was chromatographed on a silica gel column, eluting with EtOAc -hexane (1 : 3), to afford HONB (3.60g, 20mmol) and DCC (4.15g, 20mmol) were added to an ice-cooled solution of Z-Glu(OrBu)-OH (6.17g, 18 mmol) in CH3CNand the mixture was stirred for 2hours at 0°C, then the precipitates were removed by filtration. 
Synthesis of 7V-Myristoyl Derivatives 12a~12g
The 7V-myristoyl derivatives 12a~12g were obtained as white powders from the corresponding compounds (lla^llg) by 7V-acylation followed by deprotection. 
Synthesis of TV-Free Derivatives 13a~13g
The N-free derivatives 13a~13g were obtained as white powders from the corresponding compounds (lla~llg) by deprotection with TFA. 
Compound30
Chloroacetyl isocyanate (24 fA, 0.29 mmol) was added to an ice-cooled solution of lid (300mg, 0.26mmol) in CH2C12(5.0ml). The reaction mixture was stirred for 30minutes at 0°C, then concentrated. The residue was suspended in EtOAc, successively washed with 2% aqueous NaHCO3, 10% aqueous NH4C1 and water, dried over anhydrous Na2SO4,then concentrated. The residue was suspended in CH3CN and the precipitates were collected to afford a white powder (305mg, 92%). The powder (220mg, 0.17mmol) was dissolved in TFA (3.0ml), placed for 2hours at room temperature, then concentrated. The residue was suspended in CH3CN JULY 1995 and the precipitates were collected to afford 30 (189 mg, 99%) as awhitepowder:
[a]*1 -5.3°(c0.45, 5% TFA-CHC13 
Compound32
Compound 13c (5.0g) was dissolved in 20% acetonitrile-0.5% aqueous sodium hydrogen carbonate (5.0 liters) at 40°C and adjusted to pH 9.5. The solution was applied to a column of Diaion HP-20 (1.0liter), washed with 20% acetonitrile, then eluted with 40% acetonitrile (4.0liters) and 60% acetonitrile (5.0 liters). The eluate was concentrated to a small volume and lyophilized. The powder was suspended in acetonitrile (150ml) and the resulting precipitates were collected to afford 32 (4.5 g, 85%) as a white powder: [a]£5 +4.5°(c 0.57, H2O). 
Effect of Derivatives on the Proliferation of Bone Marrow Cells (BMC, in vitro)
The BMCassay was performed as described1*.
Effect of Derivatives on the Numberof White Blood
Cells (WBC, in vivo) The compounds were dissolved in 5% glucose containing an equivalent molar amount of NaOHat 2.0 mg/ml. After ultrasonic dispersion, the solution was CYand 5% glucose were administered to the CY control group in the same manner. Blood samples were collected from the orbital angular vein on day 6 using EDTA-K2treated capillary tubes. Electronics, Kobe). The ratio of the leukocyte counts (% control) was calculated from those of the vehicle control group as 100%, and the % control in CYcontrol group was 41 + 11% (mean+sd) throughout the study.
The differential leukocyte counts were examined in some experiments. Blood samples were smeared on slide glasses, stained with Giemsa solution and a total 200 leukocytes were counted. Absolute neutrophil and lymphocyte counts were calculated from the differential counts of these cells and total leukocytes.
Colony-stimulating Factor Activity in Serum
Compound33 was administered at a dose of 0.031 mg/kg on day 1 to female CDFl/Crj mice (n=3) treated with 150mg/kg of CY on day 0. Blood sample was obtained by cardiac puncture and pooled at the indicated time. Serum samples were stored at -20°C until colony assay according to Zsebo et al. with a slight modification8). Bone marrow cells (1 x 105cells) from normal CDFl/Crj mice were cultured in 6-well plates for 7 days in the presence of0.1 ml of serum in 1.0ml ofRPMI1640 medium containing 0.3% agar, 15% horse serum and 15% fetal bovine serum. Colony-stimulating factor activity (CSF activity) was expressed as the number of colonies containing more than 40 cells from 1 x 105 bone marrow cells. 
